The EMA’s CHMP recommended four new medicines in March, including opinions affecting oncology and rare-disease indications. Among the guidance, the committee backed two therapies already approved in the U.S. for extended-stage small cell lung cancer, while it declined to expand the label for Vanda’s Hetlioz in Smith-Magenis syndrome.